• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Psychiatric Medication–Induced Hyperprolactinemia

Psychiatric Medication–Induced Hyperprolactinemia

July 1, 2022
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Niki Karavitaki, MD. Senior Clinical Lecturer, Institute of Metabolism and Systems Research, University of Birmingham. Honorary Consultant Endocrinologist, Queen Elizabeth Hospital. Birmingham, UK.

Athanasios Fountas, MD. Clinical Research Fellow, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham. Birmingham, UK.

Dr. Karavitaki has disclosed that she has given webinars for Pfizer on the topic of acromegaly in February 2021 and January 2022. Dr. Hendrick has reviewed the content of this interview and determined that there is no commercial bias as a result of these financial relationships. Dr. Fountas has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A 26-year-old female patient with schizophrenia tells you she is certain she is pregnant. You run a pregnancy test, which comes back negative, but she continues to insist that she is pregnant “because I haven’t had a period in three months.” She began risperidone 2 mg twice daily about four months earlier. You check her prolactin level, and it is 105 ng/mL.

Most patients on antipsychotic medications have prolactin levels that are significantly higher than normal (>25 ng/mL for nonpregnant women and >16 ng/mL for men). You have most likely heard about missed menstrual cycles or galactorrhea (milky nipple discharge) from your female patients, while your male patients have probably complained of gynecomastia (enlarged breasts), impotence, and low sexual desire after taking antipsychotic medications. These are common manifestations of hyperprolactinemia (HPRL; see table for more). Certain antipsychotics are more likely to raise prolactin levels, especially paliperidone, risperidone, and many of the first-generation agents.

Table: Prevalence of HPRL in Patients Taking Antipsychotics
(Click to view full-size PDF.)

Why do so many antipsychotics raise prolactin levels? Normally, dopamine inhibits prolactin synthesis and secretion. Since antipsychotics block dopamine receptors, the brakes that dopamine puts on prolactin are removed, leading to higher prolactin levels. First-generation antipsychotics produce more severe HPRL (two to three times the upper limit of reference range). In contrast, second-generation antipsychotics usually produce a milder prolactin increase due to their lower affinity for the D2 receptor, with the exceptions of paliperidone and risperidone (which, especially at higher doses, increase prolactin similarly to first-generation antipsychotics).

You might be surprised to know that several antidepressants also cause HPRL, particularly clomipramine, mainly via serotonergic pathways. This effect is mostly mild and rarely symptomatic, although occasionally female patients will report galactorrhea or missed menstrual cycles; clomipramine appears to be the most likely to cause this side effect (Coker F and Taylor D, CNS Drugs 2010;24(7):563–574).

Table: “Common Manifestations of HPRL”
(Click to view full-size PDF.)

 

Should we worry about HPRL?

It’s easy to overlook HPRL because its symptoms are not readily apparent and patients are often embarrassed to tell us about them. However, ­prolactin-related side effects, if unaddressed, significantly increase medication nonadherence. HPRL causes hypogonadism by suppressing ­gonadotropin-releasing hormone, resulting in menstrual irregularities, infertility, and decreased libido in women. Men experience erectile dysfunction, reduced libido, impaired spermatogenesis, gynecomastia, anemia, decreased muscle mass, and low energy levels. Galactorrhea is a common manifestation of HPRL in ­pre-menopausal women; it is less frequent in ­post-menopausal women and rarely occurs in men.

Loss of bone density is one of the most significant long-term consequences of sustained HPRL. Many studies have reported significantly higher rates of osteoporosis and bone fractures in patients taking antipsychotic medications for schizophrenia (Stubbs B et al, Gen Hosp Psychiatry 2015;37(2):126–133).

Diagnostic approach

We recommend getting a baseline prolactin level before patients begin a psychiatric medication that is likely to cause HPRL. Check this level again in three months—sooner if you see symptoms of hyperprolactinemia. A prolactin level can be drawn at any time of day, but a few things can artificially cause a transient rise in prolactin, including exercise, nipple stimulation, and even the stress of getting stuck by a needle.

What do you do if your patient’s prolactin level is elevated? A first step is to rule out an elevated level of macroprolactin, which is a physiologically inactive form of prolactin. While few clinicians have heard about this, studies show that macroprolactin causes a false HPRL diagnosis in about 19% of cases (Che Soh NAA et al, Int J Environ Res Public Health 2020;17(21):8199). Unfortunately, not all labs offer this test. Assuming that no macroprolactin is present, your next step is to exclude other causes of increased prolactin, such as pregnancy, hypothyroidism, and kidney or liver dysfunction. A rare cause of high prolactin is a pituitary tumor, which typically presents with headaches and vision changes. If you stop the patient’s antipsychotic and the HPRL persists, consider consulting an endocrinologist, who will likely order an MRI or CT scan to rule out a pituitary tumor.

Table: Causes of HPRL Besides Antipsychotic Medication
(Click to view full-sized PDF.)

 

Management strategies

If your patient has asymptomatic HPRL, you don’t need to do anything. Continue the antipsychotic and check prolactin annually.

For patients who have symptoms, switch to a different agent with “prolactin-sparing” potential, such as aripiprazole, clozapine, or ziprasidone. Another option is to decrease the dose, as psychiatric medication–induced HPRL is usually dose related—but patients’ psychiatric symptoms might not respond well to lower antipsychotic doses. A nice psychopharm trick to have up your sleeve is adding low-dose aripiprazole (5–15 mg/day) as an adjunctive therapy. Aripiprazole reduces prolactin levels due to its partial agonistic activity at D2 receptors. Several studies have found this strategy effective (Zheng W et al, Gen Psychiatry 2019;32(5):e100091). If you’ve tried all the above and the HPRL continues, you can try prescribing a dopamine agonist such as cabergoline or bromocriptine. Be mindful that doing so will mean you are working at odds with the dopamine-blocking properties of the antipsychotic, and the patient’s psychiatric symptoms could worsen. For female patients, another option is to add a birth control pill, which will replenish estrogen that has been lowered by the prolactin. A more direct approach is using hormone replacement therapy—though this would usually be prescribed by the patient’s primary care physician or OB-GYN. 

 

Table: HPRL Management Strategies
(Click to view full-sized PDF.)

 

You switch your patient to aripiprazole 15 mg twice daily. Two weeks later, you recheck her prolactin level and find it has dropped to 22 ng/mL. A few days later, your patient informs you that her menstrual cycles have resumed.

CHPR VERDICT: Don’t ignore HPRL—switch meds, add aripiprazole, add a dopamine agonist, or encourage hormone replacement therapy. Your patients will be happy you went the extra mile!

KEYWORDS antipsychotics prolactin
www.thecarlatreport.com
Issue Date: July 1, 2022
SUBSCRIBE NOW
Table Of Contents
Psychiatric Medication–Induced Hyperprolactinemia
Minimizing the Use of Seclusion and Restraints
Treating Common Medical Conditions in Patients With Chronic Mental Illnesses
EmPATH Units: An Innovative Approach to Mental Health Crises
Lithium Exposure In Utero—How Bad Is It Really?
Antidepressants for Suicidal Ideation in Depressed Patients?
CME Post-Test - Minimizing Use of Restraints, CHPR, July/August/September 2022
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.